0001641172-25-005093.txt : 20250416 0001641172-25-005093.hdr.sgml : 20250416 20250416171127 ACCESSION NUMBER: 0001641172-25-005093 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20250416 DATE AS OF CHANGE: 20250416 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Larimar Therapeutics, Inc. CENTRAL INDEX KEY: 0001374690 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 203857670 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88225 FILM NUMBER: 25843545 BUSINESS ADDRESS: STREET 1: THREE BALA PLAZA EAST. SUITE 506 CITY: BALA CYNWYD STATE: PA ZIP: 19004 BUSINESS PHONE: 844-511-9056 MAIL ADDRESS: STREET 1: THREE BALA PLAZA EAST. SUITE 506 CITY: BALA CYNWYD STATE: PA ZIP: 19004 FORMER COMPANY: FORMER CONFORMED NAME: ZAFGEN, INC. DATE OF NAME CHANGE: 20100301 FORMER COMPANY: FORMER CONFORMED NAME: ZAFGEN INC DATE OF NAME CHANGE: 20060906 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Opaleye Management Inc. CENTRAL INDEX KEY: 0001595855 ORGANIZATION NAME: EIN: 205648796 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: ONE BOSTON PLACE STREET 2: SUITE 2600 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 617-904-9195 MAIL ADDRESS: STREET 1: ONE BOSTON PLACE STREET 2: SUITE 2600 CITY: BOSTON STATE: MA ZIP: 02108 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001595855 XXXXXXXX LIVE Common Stock 04/09/2025 0001374690 Larimar Therapeutics, Inc. 517125100 Three Bala Plaza East. Suite 506 Bala Cynwyd PA 19004 Rule 13d-1(c) Opaleye Management, Inc. MA 0.00 3952409.00 0.00 3952409.00 3952409.00 N 6.17 IA CO Opaleye, L.P. MA 0.00 3952409.00 0.00 3952409.00 3952409.00 N 6.17 OO James Silverman X1 0.00 3952409.00 0.00 3952409.00 3952409.00 N 6.17 IN Larimar Therapeutics, Inc. Three Bala Plaza East. Suite 506, Bala Cynwyd, PA, 19004 Opaleye Management, Inc. Opaleye, L.P. James Silverman This statement is filed by (i) Opaleye Management, Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to shares directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the shares reported herein. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management, Inc. - Massachusetts Opaleye, L.P. - Massachusetts James Silverman - USA Y 3,952,409 6.17 0 3,952,409 0 3,952,409 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement by and among the reporting persons Opaleye Management, Inc. /s/ James Silverman President 04/16/2025 Opaleye, L.P. /s/ James Silverman General Partner 04/16/2025 James Silverman /s/ James Silverman Individually 04/16/2025 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

JOINT FILING AGREEMENT

 

This Joint Filing Agreement, dated as of April 16, 2025, is by and among Opaleye Management, Inc., Opaleye, L.P. and James Silverman (collectively, the “Filers”).

 

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to Common Stock of Larimar Therapeutics, Inc. beneficially owned by them from time to time.

 

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

 

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

 

Executed and delivered as of the date first above written.

 

  OPALEYE MANAGEMENT, INC.
     
  By: /s/ James Silverman
  Name: James Silverman
  Title: President
     
  OPALEYE, L.P.
     
  By: /s/ James Silverman
  Name: James Silverman
  Title: General Partner
     
  JAMES SILVERMAN
     
  /s/ James Silverman